Ilumya is given as by subcutaneous injection, which means under the skin. Ilumya must be administered by a healthcare professional who will choose an injection site with clear skin and easy access, such as your abdomen (stomach), thighs, or upper arm. Ilumya should not be administered within 2 inches of the navel or where the skin is tender, bruised, red, or affected by psoriasis. It should also not be injected into scars, stretch marks, or blood vessels.

The first two injections of Ilumya are given 4 weeks apart, followed by an injection thereafter once every 12 weeks. Each single-dose prefilled syringe of Ilumya contains 100 mg of tildrakizumab-asmn. Ilumya cannot be self-administered.

In March 2018, the FDA approved Ilumya (tildrakizumab-asmn), a humanized interleukin-23 p19 subunit antagonist (anti-IL-23p19) monoclonal antibody for moderate-to-severe plaque psoriasis in adults who are candidates for systemic treatment or phototherapy (ultraviolet or UV light).